RenovoRx (RNXT) Announces Leadership Changes

RenovoRx, Inc. (Nasdaq: RNXT) today highlighted the recent key leadership promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Officer.

Shaun Bagai, Chief Executive Officer of RenovoRx, commented, “We are delighted to promote Leesa and Ron to their new leadership roles, which reflects our commitment to assembling a dynamic team poised to continue to lead a successful clinical pathway for our proprietary therapy platform. We have streamlined our team, focusing our efforts on strategic initiatives to drive growth and innovation. On behalf of our Board of Directors, I extend our gratitude to Leesa and Ron on their hard work and dedication to date and congratulate them on their well-deserved promotions.”

Ms. Gentry has served as Senior Vice President of Clinical Operations at RenovoRx since April 2023. In her new role as Chief Clinical Officer, she will oversee clinical and regulatory operations ensuring the highest standards for safety and quality are met across RenovoRx clinical studies. Ms. Gentry will continue to implement her breadth of experience as the Company drives towards a second interim analysis for the Phase III TIGeR-PaC study evaluating RenovoRx’s lead product candidate, RenovoGemTM for the treatment of Locally Advanced Pancreatic Cancer (LAPC), which is expected by late 2024.

Since joining RenovoRx, Ms. Gentry has demonstrated exemplary leadership and commitment to advancing the Company’s clinical pipeline. In 2023, Ms. Gentry helped to achieve the first interim analysis in the TIGeR-PaC with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study’s primary endpoint is a 6-month Overall Survival benefit with secondary endpoints including reduced side effects versus standard of care. Under her guidance, the Company’s clinical strategy to date has yielded positive results that contribute to the Company’s commitment to improve patients’ lives and lifespans by delivering therapies that have the potential to revolutionize the current paradigm of cancer care.

Mr. Kocak has been promoted to the position of Principal Accounting Officer and will retain his roles as Vice President and Controller of RenovoRx. He joined the Company in October 2021 and is a seasoned financial reporting and accounting professional with extensive public and private company experience in the life sciences industry. Mr. Kocak was instrumental in the recent completion of a $6.1 million private placement that extended RenovoRx’s cash runway to support its clinical program initiatives. In this new leadership role, Mr. Kocak will oversee all financial management, reporting and strategic planning initiatives crucial to furthering the Company’s research and development efforts.

You May Also Be Interested In

• RenovoRx regains Nasdaq minimum bid price compliance
• RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
• Albemarle names Max Hood as chief accounting officer